Balyasny Asset Management
TSHA icon

Balyasny Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Balyasny Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Buy
189,332
+106,313
+128% +$629K ﹤0.01% 2068
2026
Q1 		$371K Buy
83,019
+40,949
+97% +$190K ﹤0.01% 2482
2025
Q4 		$231K Buy
+42,070
New +$204K ﹤0.01% 2831
2024
Q2 		– Sell
-188,698
Closed -$542K – 3121
2024
Q1 		$542K Buy
+188,698
New +$393K ﹤0.01% 2020

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Balyasny Asset Management's TSHA Position: Q2 2026 in Review

Balyasny Asset Management increased its Taysha Gene Therapies (TSHA) stake by 128% in Q2 2026, buying an estimated $629K and bringing the position to 189,332 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2068.

Balyasny Asset Management first reported a position in TSHA in Q1 2024 and has held it in 4 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Balyasny Asset Management held 189,332 shares of Taysha Gene Therapies worth $1.29M as of Q2 2026.
  • Balyasny Asset Management bought 106,313 Taysha Gene Therapies shares in Q2 2026, an estimated $629K.
  • Taysha Gene Therapies made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2068 holding.
  • Balyasny Asset Management first reported a position in Taysha Gene Therapies in Q1 2024 and has held it in 4 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.